News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
641,912 Results
Type
Article (61471)
Company Profile (73)
Press Release (580368)
Section
Business (174412)
Career Advice (2730)
Deals (32513)
Drug Delivery (96)
Drug Development (77009)
Employer Resources (148)
FDA (14929)
Job Trends (13904)
News (305997)
Policy (29138)
Tag
Academia (2875)
Alliances (43262)
Alzheimer's disease (1253)
Approvals (14926)
Artificial intelligence (204)
Bankruptcy (289)
Best Places to Work (10875)
Breast cancer (224)
Cancer (1662)
Cardiovascular disease (121)
Career advice (2310)
CAR-T (124)
Cell therapy (356)
Clinical research (61968)
Collaboration (622)
Compensation (226)
COVID-19 (2552)
C-suite (173)
Data (1596)
Diabetes (195)
Diagnostics (6081)
Earnings (59542)
Employer resources (131)
Events (93501)
Executive appointments (590)
FDA (15829)
Funding (600)
Gene therapy (239)
GLP-1 (608)
Government (4428)
Healthcare (18227)
Infectious disease (2655)
Inflammatory bowel disease (120)
Interviews (524)
IPO (14777)
Job creations (3440)
Job search strategy (1945)
Layoffs (469)
Legal (6534)
Lung cancer (242)
Manufacturing (213)
Medical device (12571)
Medtech (12576)
Mergers & acquisitions (18149)
Metabolic disorders (502)
Neuroscience (1644)
NextGen: Class of 2025 (6392)
Non-profit (4331)
Northern California (1876)
Obesity (267)
Opinion (219)
Patents (160)
People (59164)
Phase I (19491)
Phase II (27362)
Phase III (19948)
Pipeline (672)
Postmarket research (2485)
Preclinical (8252)
Radiopharmaceuticals (243)
Rare diseases (307)
Real estate (5997)
Regulatory (19854)
Research institute (2398)
Resumes & cover letters (405)
Southern California (1653)
Startups (3341)
United States (16886)
Vaccines (592)
Weight loss (176)
Date
Today (9)
Last 7 days (545)
Last 30 days (2330)
Last 365 days (31768)
2025 (4221)
2024 (32358)
2023 (36445)
2022 (46740)
2021 (51698)
2020 (50836)
2019 (44929)
2018 (34177)
2017 (30803)
2016 (30173)
2015 (35584)
2014 (28545)
2013 (25097)
2012 (26381)
2011 (26623)
2010 (25106)
Location
Africa (873)
Arizona (155)
Asia (37806)
Australia (6806)
California (4297)
Canada (1618)
China (363)
Colorado (200)
Connecticut (218)
Europe (88217)
Florida (646)
Georgia (159)
Illinois (465)
Indiana (234)
Japan (112)
Maryland (696)
Massachusetts (3133)
Michigan (200)
Minnesota (286)
New Jersey (1279)
New York (1250)
North Carolina (829)
Northern California (1876)
Ohio (163)
Pennsylvania (979)
South America (1176)
Southern California (1653)
Texas (656)
Utah (135)
Washington State (433)
641,912 Results for "university of british columbia".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Medexus and British Columbia’s Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
January 15, 2025
·
8 min read
Policy
PreveCeutical Commences Litigation Against Former Legal Counsel in the British Columbia Supreme Court Alleging Professional Negligence
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), announces that it, along with certain others, filed a Notice of Civil Claim (the “Claim”) in the British Columbia Supreme Court on June 5, 2024 against its former legal counsel (the “Defendants”).
June 6, 2024
·
5 min read
Cell MedX Corp. Announces Full Revocation of British Columbia Cease Trade Order
Cell MedX Corp. (“Cell MedX” or the “Company”) (OTC Pink: CMXC) announces that on November 22, 2023, the British Columbia Securities Commission
November 28, 2023
·
4 min read
Press Releases
Alaya.bio Expands in situ CAR-T Therapy Collaboration with Michel Sadelain and Columbia University
January 21, 2025
·
2 min read
Press Releases
Vector Laboratories Announces Partnership With British Biotech Innovator Etcembly
February 20, 2025
·
3 min read
Press Releases
Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada and British Columbia to Advance Development of Bioprinted Tissue Therapeutics
July 23, 2024
·
3 min read
Press Releases
Baird Medical Advances MWA Training with Expert-Led Course at Columbia Thyroid Center
February 10, 2025
·
4 min read
Andira Advances Lead Cannabinoid Compositions for Metastatic Breast Cancer through a Collaborative Research Agreement with Canada Research Chair in Oncology Dr. Karla Williams at the University of British Columbia
Andira Pharmaceuticals announces it will carry out pharmacologic characterization of its lead compounds for metastatic breast cancer through a collaborative research program with the University of British Columbia (UBC), Vancouver.
March 22, 2023
·
3 min read
Mitsubishi Tanabe Pharma Canada Announces That Company’s Oral Treatment Formulation for Amyotrophic Lateral Sclerosis (ALS) Has Been Added to the Provincial Drug Plan in British Columbia
Mitsubishi Tanabe Pharma Canada, a subsidiary of Mitsubishi Tanabe Pharma America, Inc., announced that RADICAVA® Oral Suspension is now covered under British Columbia PharmaCare for the treatment of people living with amyotrophic lateral sclerosis, a rapidly progressive, neurodegenerative disease.
August 18, 2023
·
4 min read
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
AbCellera (Nasdaq: ABCL) today announced a CA$701 million co-investment with the Governments of Canada and British Columbia to build new capabilities and infrastructure to develop innovative antibody-based medicines and strengthen Canada’s leadership in clinical research, manufacturing, and drug development.
May 24, 2023
·
8 min read
1 of 64,192
Next
